Shanghai Labway Clinical Laboratory Co., Ltd (SHE:301060)
China · Delayed Price · Currency is CNY 11.33
+0.07 (0.62%)
Feb 4, 2026, 3:04 PM CST
SHE:301060 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Net Income | -69.52 | -109.44 | -141.59 | 617.32 | 203.84 | 110.38 |
Depreciation & Amortization | 73.28 | 73.28 | 65.36 | 78.24 | 59.35 | 43.69 |
Other Amortization | 30.33 | 30.33 | 18.08 | 20.03 | 11.24 | 9.23 |
Loss (Gain) From Sale of Assets | -5.88 | -5.88 | -1.93 | 0.36 | -1.04 | -0.65 |
Asset Writedown & Restructuring Costs | 15.89 | 15.89 | 11.07 | 158.37 | 1.07 | 17.77 |
Loss (Gain) From Sale of Investments | 12.17 | 12.17 | 1.77 | -3.13 | -10.17 | -7.41 |
Provision & Write-off of Bad Debts | 25.67 | 25.67 | 130.67 | 55.77 | 15.26 | - |
Other Operating Activities | 232.69 | 72.57 | 6.05 | 140.67 | 67.51 | 24.34 |
Change in Accounts Receivable | 218.81 | 218.81 | 1,061 | -1,522 | -298.03 | -82.46 |
Change in Inventory | 9.43 | 9.43 | 14.84 | -273.18 | 0.69 | 21.94 |
Change in Accounts Payable | -121.58 | -121.58 | -604.36 | 828.74 | 173.11 | 35.19 |
Change in Other Net Operating Assets | 19.93 | 19.93 | 5.09 | - | - | - |
Operating Cash Flow | 416.35 | 216.31 | 546.99 | 84.17 | 223.51 | 167.87 |
Operating Cash Flow Growth | 58.42% | -60.45% | 549.88% | -62.34% | 33.14% | 137.77% |
Capital Expenditures | -60.97 | -76.62 | -398.89 | -230.08 | -118.88 | -44.55 |
Sale of Property, Plant & Equipment | 5.84 | 5.6 | 3.99 | 4.68 | 5.49 | 7.96 |
Cash Acquisitions | - | - | -11.1 | - | - | - |
Divestitures | 3.53 | 3.8 | - | 0 | - | - |
Investment in Securities | 2 | -2 | 6.94 | 395.94 | -296.9 | 111.55 |
Other Investing Activities | 2.91 | 0.63 | 0.56 | 9.51 | 6.88 | 8.76 |
Investing Cash Flow | -46.69 | -68.58 | -398.5 | 180.05 | -403.41 | 83.72 |
Short-Term Debt Issued | - | - | - | - | 4 | - |
Long-Term Debt Issued | - | 122.93 | 368.64 | 198.01 | - | - |
Total Debt Issued | 50 | 122.93 | 368.64 | 198.01 | 4 | - |
Short-Term Debt Repaid | - | - | - | - | -2 | - |
Long-Term Debt Repaid | - | -236.09 | -186.68 | -35.45 | -18.77 | - |
Total Debt Repaid | -159.69 | -236.09 | -186.68 | -35.45 | -20.77 | - |
Net Debt Issued (Repaid) | -109.69 | -113.16 | 181.96 | 162.57 | -16.77 | - |
Issuance of Common Stock | - | - | - | - | 158.55 | - |
Repurchase of Common Stock | -12.75 | -12.75 | -10.26 | - | - | - |
Common Dividends Paid | -84.34 | -7.36 | -136.71 | -125.61 | -0.3 | -35.27 |
Dividends Paid | -84.34 | -7.36 | -136.71 | -125.61 | -0.3 | -35.27 |
Other Financing Activities | -101.58 | -46.99 | 9.74 | 13.53 | -21.73 | -60.85 |
Financing Cash Flow | -308.36 | -180.25 | 44.73 | 50.48 | 119.75 | -96.11 |
Foreign Exchange Rate Adjustments | 0.34 | - | -0.57 | -0.56 | 0.02 | -0.24 |
Net Cash Flow | 61.63 | -32.52 | 192.65 | 314.15 | -60.12 | 155.25 |
Free Cash Flow | 355.38 | 139.7 | 148.1 | -145.91 | 104.63 | 123.33 |
Free Cash Flow Growth | 116.15% | -5.68% | - | - | -15.16% | 296.69% |
Free Cash Flow Margin | 23.32% | 8.02% | 8.85% | -3.48% | 5.88% | 9.96% |
Free Cash Flow Per Share | 0.88 | 0.34 | 0.37 | -0.36 | 0.30 | 0.35 |
Cash Income Tax Paid | 49.23 | 48.43 | 121.5 | 194.14 | 77.25 | 64.4 |
Levered Free Cash Flow | 340.83 | 187.84 | 207.16 | -378.79 | 38.83 | 112.42 |
Unlevered Free Cash Flow | 345.58 | 194.6 | 212.26 | -373.5 | 40.87 | 112.42 |
Change in Working Capital | 101.72 | 101.72 | 457.5 | -983.47 | -123.55 | -29.48 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.